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Background: Previous data have shown that ghrelin-induced growth hormone (GH) secretion is augmented in
women by exogenous but not by endogenous estrogens. The purpose of this study was to examine the response
of GH to low-dose scheme of ghrelin administration in relation to physiological changes in estradiol levels during
the normal menstrual cycle.
Methods: Ten normally cycling women were studied in two menstrual cycles. Two consecutive dosages of ghrelin
(0.15 μg/kg and 0.30 μg/kg) were injected intravenously at 0 and 90 min in the early and late follicular phases of
one cycle. Saline was injected in the preceding cycle. Blood samples were taken at −15, 0, 30, 60, 90, 120, 150 and
180 min. The GH response was assessed.
Results: Serum estradiol concentrations were significantly higher in the late than in the early follicular phase. After
ghrelin, but not after saline administration, plasma ghrelin and serum GH levels increased significantly in both
phases, peaking at 30 min and 120 min. The peak value at 120 min was significantly higher than at 30 min
(P<0.001). There were no significant differences in ghrelin and GH levels between the two phases at all time points.
Conclusions: The present results show no difference in GH response to two consecutive submaximal doses of
ghrelin between the early and the late follicular phase of the cycle. It is suggested that estradiol is not possibly
involved in the physiological process that regulates ghrelin-induced GH secretion in women during the normal
menstrual cycle.
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Ghrelin is a 28-amino acid protein, which is produced in
the mucosa of the stomach but it is also expressed in
other tissues. This substance is considered the endogen-
ous ligand for the growth hormone secretagogue recep-
tor (GHS-R) [1]. Various experiments in animals and
humans have shown that ghrelin stimulates the secretion
of GH together with other pituitary hormones, such as
prolactin and adrenocorticotrophic hormone [2]. A role
for ghrelin in the regulation of reproductive function has
been suggested both in animals and in humans [3-5]. A* Correspondence: messinis@med.uth.gr
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reproduction in any medium, provided the orpossible site of action is the ovaries [6,7], affecting ste-
roidogenesis in humans [8], while an inhibitory effect on
LH and FSH secretion has been shown in animals, men
and women [9-13].
Previous studies have shown that acylated and un-
acylated ghrelin and GH levels do not change significantly
during the normal menstrual cycle [14,15]. It has been also
demonstrated that the stimulating action of ghrelin on
GH secretion is affected by ovarian steroids. This is based
on experiments performed in postmenopausal women
treated with the exogenous administration of estradiol or
the combination of estradiol plus dydrogesterone [16-18].
In the two studies with estradiol alone, an enhancing effect
of this steroid on ghrelin-induced GH secretion was ob-
served with the use of either a single submaximal dose ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wise, every 90 min, increase [17]. A more recent study,
however, in normally cycling women has not shown any
difference in the GH response to a single relatively high
dose of ghrelin among three different phases of the cycle
despite marked changes in ovarian steroids concentrations
including estradiol [15]. Whether, under these conditions,
low-dose schemes of ghrelin stimulation, as compared to a
single high dose, could provide different GH responses,
has not been investigated.
The present study was undertaken to investigate the
hypothesis that the effect of two consecutive sub-
maximal doses of ghrelin on GH secretion in the early
and the late follicular phase of the menstrual cycle is not
affected by changes in the physiological concentrations
of estradiol in normal women.
Methods
Subjects
Ten normally cycling women (aged 22.8±3.7 years, BMI
21.0±3.4 kg/m2, mean±SD) were included. The length of
the menstrual cycle was 27–28 days. The women volun-
teered for the study and gave written informed consent.
Approval for the study was obtained from the local Ethi-
cal Committee. Ovulation was confirmed before the on-
set of the study by serum progesterone measurement
and ultrasound scans of the ovaries. The women were
not taking any hormonal or any other medical treatment
for the last 6 months before entering the study. They
had normal thyroid and adrenal function, while serum
prolactin levels were within the normal range. All
women were investigated during two menstrual cycles.
In each cycle the same experimental procedure was per-
formed twice, i.e. in the early follicular phase (cycle day
2) and in the late follicular phase, when the size of the
dominant follicle, as assessed by ultrasound reached the
diameter of 16–17 mm. In both cycles, after overnight
fasting, the women were admitted to the clinical re-
search unit around 0930 h. An indwelling cannula was
inserted in the forearm vein and the women were left to
relax for about 15 min. Then, a blood sample was taken
(time −15 min) and a second one 15 min later (time
0 min). Immediately after the second blood sample was
obtained, in the second cycle (study cycle) a single dose
of 0.15 μg/kg ghrelin was given to the women as an
acute i.v. injection. Further blood samples, in relation to
time 0, were taken at 30, 60, 90, 120, 150 and 180 min.
A second dose of 0.30 μg/kg ghrelin was injected imme-
diately after the 90 min blood sample. The same experi-
mental procedure was performed twice in the first cycle
preceding the study cycle with the difference that instead
of ghrelin, 2 ml of normal saline was injected i.v. at 0
and 90 min (control cycle). All blood samples were
centrifuged at 1000 g for 15 min and serum and plasmawere stored at −20°C until assayed. In all blood samples,
GH was measured. Ghrelin was measured in the samples
from −15 to 120 min inclusive, while estradiol and pro-
gesterone were measured only in the 0 min sample. No
side effects were seen in any of the women following the
administration of ghrelin.
Hormone assays
Measurement of total ghrelin in plasma was performed
using a radioimmunoassay (KIPMR90, DIASource Immu-
noAssays S.A., Louvain-la-Neuve, Belgium) and the results
are expressed as pg/ml. Measurement of GH in serum was
performed using an immunoradiometric assay (hGH-
IRMA, IMMUNOTECH S.A.S., Marseille Cedex, France)
and the results are expressed as ng/ml. Estradiol was
measured in serum using a radioimmunoassay (RIA-
ESTRADIOL, IMMUNOTECH S.A.S., Marseille Cedex,
France). The results are expressed as pg/ml. Measurement
of progesterone in serum was performed with the use of a
radioimmunoassay (PROG-RIA-CT, DIASourse Immuno-
Assays S.A., Louvain-la-Neuve, Belgium). The results are
expressed as ng/ml. The lower limits of detection for
ghrelin, GH, estradiol and progesterone were 40 pg/ml,
0.03 ng/ml, 6.0 pg/ml and 0.05 ng/ml respectively. Inter-
and intra-assay coefficients of variation were 7.1 and 4.2%,
8.7 and 0.9%, 8.5 and 7.5% and 6.8 and 4.2% respectively.
Statistical analysis
Hormone values were normally distributed (one sample
Kolmogorov-Smirnov test) and statistical analysis was
performed by repeated measures one-way analysis of vari-
ance (ANOVA) followed by Bonferroni post hoc testing
and paired t-test. An a level of 0.05 was used to determine
statistical significance. All values are expressed as mean±
SD. The statistical software package used was NCSS
2001 (Number Cruncher Statistical Systems, Kaysville,
UT, USA).
Results
Serum estradiol concentrations on day 2 were similar in
the two cycles (control cycle: 30.5±5.0 pg/ml, study cycle:
26.1±4.6 pg/ml). Follicle size (mean diameter of two mea-
surements) and serum estradiol values (time 0 min) on the
day of the experiment in the late follicular phase were
similar in the two cycles (16.4±0.2 and 16.5±0.2 mm and
133.1±22.6 and 126.5±23.4 pg/ml respectively). Estradiol
values in the late follicular phase were significantly higher
than in the early follicular phase in both cycles (P<0.001).
Serum progesterone values were low in both phases of the
cycle with no difference between the two cycles (mean
value <1 ng/ml).
Figure 1 shows plasma ghrelin and serum GH levels
during the two experiments. Plasma ghrelin concentra-
tions were similar in the two cycles both in the early
Figure 1 Plasma ghrelin and serum GH values in (a and c) early (cycle day 2) and (b and d) late follicular phase of the cycle (follicle
size 16–17 mm) in 10 normally cycling women before (time −15 and 0 min) and after the i.v. injection (arrows) of (●) ghrelin (0.15 μg/kg at
0 min and 0.30 μg/kg at 90 min) or (o) saline (2 ml at 0 and 90 min). **P<0.001, *P<0.05 (difference from saline experiments).
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fore the onset of the experiment (time 0 min). Ghrelin
values increased significantly after each ghrelin injection.
Peak values were seen at 30 min (early follicular: 6049±
181, late follicular: 5703±362 pg/ml) and 120 min (early
follicular: 8010±228, late follicular: 7613±370 pg/ml),
but the peak at 120 min was significantly higher than at
30 min in both phases (P<0.001). Plasma ghrelin values
were significantly lower at 90 min than at 30 min and at
150 and 180 min than at 120 min in both phases
(P<0.001) (Figure 1). The peak values of ghrelin at 30
and 120 min in the early follicular phase were similar to
those in the late follicular phase respectively (Figure 2a
and b). In the control cycle, plasma ghrelin values did
not change significantly following the administration of
saline but remained stable throughout the experimental
procedure in both phases with no difference between
them at all time points (Figure 1). Plasma ghrelin con-
centrations were significantly higher in the study cycle
than in the control cycle at 30, 60, 120 and 150 min
(P<0.001) as well as at 180 min (P<0.05) in both phases
(Figure 1a and b).
Serum GH values were similar before the onset of the
experiment (time 0 min) in the two phases of the cycle
both in the control and the study cycle (Figure 1). Fol-
lowing the first injection of ghrelin, serum GH levels in-
creased significantly at 30 min both in the early (51.0±
5.1 ng/ml, P<0.001, Figure 1c) and the late follicular
phase (55.3±4.7 ng/ml, P<0.001, Figure 1d). Then, GHvalues returned to the baseline at 60 and 90 min
(P<0.001), but increased again significantly at 120 min
following the second injection of ghrelin in the early
(76.0±5.0 ng/ml, P<0.001, Figure 1c) and the late follicu-
lar phase (75.2±11.3 ng/ml, P<0.001, Figure 1d). The
peak value at 120 min was significantly higher than
the peak value at 30 min in both phases of the cycle
(P<0.001). A significant decrease in GH levels was seen at
150 and 180 min as compared to the 120 min levels in
both phases of the cycle (P<0.001, Figure 1c and d). The
peak values of GH at 30 and 120 min in the early follicular
phase were similar to those in the late follicular phase re-
spectively (Figure 2). In the saline experiments, serum GH
values remained constant with no significant difference
between the two phases at all time points. Serum GH
values at 30 and 120 min were significantly higher in the
study cycle than in the control cycle in both phases
(P<0.001) (Figure 1c and d). The pattern of changes in
serum GH values was in both phases of the study cycle al-
most identical to those of plasma ghrelin values.
Discussion
The present study confirms that the exogenous adminis-
tration of ghrelin stimulates in women the secretion of
GH leading to a significant increase in serum concentra-
tions of this hormone [2,15]. In this study, however, we
used two submaximal but still pharmacological doses of
ghrelin and found that the response of GH was dose-
dependent. Previous studies in postmenopausal women
Figure 2 Plasma ghrelin and serum GH values in early (EF) and late follicular phase of the cycle (LF) in 10 normally cycling women (□)
before (time 0 and 90 min) and (■) after (time 30 and 120 min) the i.v. injection of ghrelin at the dose of (a and c) 0.15 μg/kg and (b and d)
0.30 μg/kg. **P<0.001 (difference between 30 and 0 min and between 120 and 90 min).
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phase’, created after the exogenous administration of es-
trogens, the stimulating effect of a single or multiple doses
of ghrelin on GH secretion was enhanced as estradiol con-
centrations increased [16,17]. This, however, was not con-
firmed in a more recent study in which the stimulating
action of a single dose of ghrelin (1 μg/kg) on GH secre-
tion was not affected by changes in the endogenous hor-
monal profile, such as the increasing concentrations of
estradiol during the follicular phase of the cycle [15]. It
was considered then, that multiple submaximal dosages of
ghrelin might be more physiological than a single high
dose. Nevertheless, this does not seem to be the case,
since in the present study using submaximal dosages of
ghrelin, we did not find any significant difference in GH
response between the two stages of the cycle. In addition,
when ghrelin was given in a previous study as a bolus at
the dose of 1 μg/kg to a group of normal postmenopausal
women treated for 60 days with the combination of 2 mg
estradiol and 10 mg dydrogesterone, the GH response to
that dose was also enhanced by these steroids [18]. It is
suggested, therefore, that it is not the amount of ghrelin
that accounts for the different results between the present
and the previous studies.
It should be emphasized that the enhanced response
of GH secretion to ghrelin in the previous studies was
seen after the administration of exogenous estrogens,
while in this study we took into account only endogenous
estrogens. In addition to that, in the previous studies[16,17], the role of endogenous estrogens was not investi-
gated, while the women who were included were post-
menopausal. However, the model of postmenopausal
women may not be the most appropriate, since due to the
long-term oestrogen deprivation, the integrity of the
hypothalamic-pituitary system may have been compro-
mised. Previous data have shown a reduction in the circu-
lating concentrations of GH with ageing [19], while the
response of GH to ghrelin was attenuated in the elderly as
compared to young male or female subjects [20]. It is pos-
sible, therefore, that the enhanced response of GH to
ghrelin in postmenopausal women following the adminis-
tration of oestrogens is explained on the basis of a restor-
ation of the impaired pituitary function by these steroids,
which rendered the pituitary cells more sensitive to the
different secretagogues. In addition to these, previous data
have shown that postmenopausal women demonstrate a
reduced GH response to various secretagogues as com-
pared to premenopausal women [21]. It has been shown
previously that in experiments involving the administra-
tion of estradiol in combination with exogenous ghrelin to
postmenopausal women, it was possible to predict night-
time production rates of acylated ghrelin, in the context of
increased synthesis and/or acylation of ghrelin peptide
by estradiol [22]. Whether endogenous estrogens could
have a similar effect on ghrelin synthesis has not been
investigated.
Regarding the use of GH secretagogues other than
ghrelin, inconsistent results have been obtained. In the
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stances was enhanced by exogenous estradiol even if the
dose utilized was rather high. For instance, the response
to a single dose of 3 μg/kg of GHRP-2 was enhanced by
estradiol treatment in postmenopausal women [23]. In
contrast, an enhanced response of GH was not seen
when hexarelin was used as a stimulus at the dose of
2 μg/kg and the women were treated with transdermal
estradiol for three months [24]. Nevertheless, in none of
these studies the role of endogenous estrogens was
investigated.
It is likely that the present experiments, performed in
the presence of naturally increasing levels of estradiol
during the follicular phase of the cycle, provide a more
physiological way to investigate the role of estrogens on
the endocrine actions of ghrelin rather than during a
‘simulated’ mode of estradiol increase. Certainly, this is a
pharmacological study and not necessarily applying to
the physiology. The investigation of the pulsatile secre-
tion of acylated ghrelin in conjunction with GH secre-
tion might be more appropriate, but this could be the
aim of a new study with a different design. Although it
might be that GH secretion in response to ghrelin is
controlled differentially by endogenous and exogenous
ovarian steroids [15], understanding the role of ghrelin
on GH secretion during the normal menstrual cycle will
certainly require a sophisticated rather than a simplified
approach, as it is the use of various pharmacological
tools.
Conclusions
The present results show for the first time that the re-
sponse of GH to two consecutive submaximal doses of
ghrelin was similar in the early and the late follicular
phase of the cycle. Since great hormonal differences
occur between these two stages, it is suggested that es-
tradiol is not possibly involved in the physiological
process that regulates ghrelin-induced GH secretion in
women during the normal menstrual cycle.
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